NEUCA S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 904 PLN | +1.01% |
|
+0.56% | -2.27% |
| Mar. 23 | NEUCA S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | NEUCA S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Neuca SA is a Poland-based company, which operates in the healthcare market. The Company is mainly involved in the distribution of drugs to pharmacies. It also operates in other sectors of the health market, such as production of drugs, supplements and cosmetics under its own brand, clinical trials, telemedicine, Information Technology (IT) solutions and e-commerce in the health care industry.
Sector
Pharmaceuticals
Calendar
2024-05-22
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
904
PLN
Average target price
974.7
PLN
Spread / Average Target
+7.82%
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -2.27% | 998M | |
| +17.35% | 71.39B | |
| +2.39% | 25.1B | |
| +5.38% | 8.59B | |
| +6.69% | 8.19B | |
| -20.96% | 7.91B | |
| +0.49% | 4.54B | |
| +17.12% | 4.31B | |
| -2.61% | 3.86B | |
| +22.08% | 3.64B |
- Stock Market
- Equities
- NEU Stock
- News NEUCA S.A.
- ODI Pharma’s Stock Soars After Exclusive Supplier Deal With Synoptis Pharma
